Can a single dose ease fragile x? new trial tests three drugs

NCT ID NCT05418049

Ongoing Symptom relief Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of baclofen, roflumilast, or memantine can improve brain activity and symptoms in adults with Fragile X syndrome. Forty-five participants aged 18 to 45 will receive each drug or a placebo in separate sessions. The main goal is to measure changes in brain waves using EEG, along with clinician and caregiver ratings of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baclofen, roflumilast, memantine
What this could lead to: If successful, this could point toward a short-term treatment to ease certain symptoms of Fragile X syndrome.
What could go wrong: This is an early phase 2 trial with only 45 participants, testing single doses. It may not show clear benefits, and results may not apply to long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fragile X syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILE X SYNDROME

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.